Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Fundamentals of Liver Disease - Hepatitis C 2.0

    Contains 28 Component(s), Includes Credits Recorded On: 02/26/2021

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    KEY TOPIC AREAS
    HCV: Epidemiology and Screening
    Patient with New Diagnosis of HCV (anti-HCV positive)
    Assessing Severity of Liver Disease in HCV
    Management of the Patient with Chronic HCV
    Management of the Chronic HCV Patient with Co-Morbid and Other Conditions
    Antiviral Treatment of the Patient with HCV Infection
    Management of Patients with HCV who have Achieved a Virological "Cure"
    The Pediatric Patient with HCV

    Release date: February 26, 2021
    Expiration date: February 25, 2024
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 4.00 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points

    COMPONENTS
    Online presentations comprised of:

    -8 online interactive, narrated modules 15 to 20 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points
    Continuing Education (CE): For a maximum of 4.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS 
    Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 4.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 25, 2024

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.00 contact hours for this enduring continuing education material must be completed by February 25, 2024

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by February 25, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through February 2024 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    John W. Ward, MD
    Faculty
    General non-binding support: Abbott, Roche, AbbVie, Siemens, AASLD, EASL, Zydus Cadilla, Cepheid, Asian Liver Center, John Martin Foundation, Gilead Sciences, US CDC, PHARCO and individuals

    Nancy Reau, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead Sciences
    Faculty/Advisory Committee or Review Panels: AbbVie, Gilead Sciences

    Jordan J. Feld, MD, MPH, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Eiger, Enanta, Gilead Sciences, Janssen and Wako/Fujifilm
    Faculty/Advisory Committee or Review Panels: AbbVie, Arbutus, Eisai, Gilead Sciences, GSK and Roche

    Sanjeev Arora, MD, FAASLD
    Faculty
    Nothing to disclose

    Raymond T. Chung, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead Sciences, Merck, BMS, Janssen, Boehringer and Roche

    Jennifer Price, MD, PhD
    Faculty
    Grant/Research Support: Gilead Sciences and Merck
    Consulting: Theratechnologies
    Ownership Interest (Spouse): AbbVie, Bristol-Myers Squibb, Johnson and Johnson and Merck

    Michael W. Fried, MD, FAASLD
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and multiple NIH Grants
    Consulting: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen and Merck

    Andrew J. Muir, MD, FAASLD
    Grant/Research Support: AbbVie, Gilead Sciences and Merck
    Faculty/Advisory Committee or Review Panels: AbbVie and Gilead Sciences

    Kathleen B. Schwarz, MD, FAASLD
    Grant/Research Support: NIDDK, Roche/Genentech and Gilead Sciences
    Consulting: Sarepta, Up-to-Date and Mirium 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Leslie Hayes, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Sonal Kumar, MD
     
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.


  • 2021 Webinar: Use of Serum and Imaging Biomarkers of NAFLD/NASH in Clinical Practice

    Contains 2 Component(s) Recorded On: 02/17/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on February 17, 2021.

    This on-demand webinar will update the audience on the most recent data in non-invasive testing (NITs) biomarkers in NAFLD/NASH (including use for staging, monitoring disease progression and response to therapy). We will focus on three key areas: serum-based biomarkers, imaging-based biomarkers and how to use combination or sequential NITs. At the conclusion of the webinar, learners will have an update on knowledge of various biomarkers in NAFLD and a path to apply best practices in their setting.

    Emmanuel A. Tsochatzis

    Emmanuel A. Tsochatzis, MD, PhD, MSc, FEBTM, FRCP is a professor of hepatology at the UCL Institute for Liver and Digestive Health in the Royal Free Hospital, London, UK and head of the Centre for Metabolic Liver Diseases. He leads the specialist multidisciplinary service in NAFLD at the Royal Free Hospital and has an active research program in NAFLD. His clinical and research interests include NAFLD, non-invasive fibrosis assessment, cirrhosis and portal hypertension. Professor Tsochatzis finished his specialty training and PhD in Hippokration General Hospital in Greece, before moving to the Royal Free Hospital for his post-doc research under Professor Andy Burroughs. Since 2019, he is a member of the Scientific Committee and Governing Board of EASL.

    Professor Tsochatzis is the section editor for liver disease in BMC Gastroenterology and in the editorial board of Liver International. He was a member of the editorial board of HEPATOLOGY from 2017 to 2019. He is a member of the steering committee of the Baveno collaboration for portal hypertension. He led several international research collaborations resulting in more than 220 publications in peer reviewed journals. His work on the cost-effectiveness of non-invasive fibrosis tests has informed the WHO guidelines on diagnosis and treatment of both HBV and HCV. He designed and implemented a primary care pathway for NAFLD referrals to secondary care. He received funding for his research from NIHR, EASL and EU Horizon 2020.

    Mohammad Shadab Siddiqui

    Mohammad Shadab Siddiqui, MD is an associate professor of medicine at Virginia Commonwealth University in the Division of Gastroenterology and Hepatology. His clinical and research interest are largely in nonalcoholic fatty liver disease (NAFLD). More specifically, he is interested in the liver-heart axis and metabolic complications of NAFLD. This research spans full spectrum on NAFLD that includes early disease, cirrhosis and post-LT NAFLD. He also has an interest in biomarker development and regulatory science. In his publications, he demonstrated the impact that NAFLD has on lipoprotein metabolism and the clinical implications of this impact. His work in the cirrhosis cohort attempted to better define cardiovascular risk assessment prior to liver transplantation. Furthermore, his publications have also provided additional insight on CVD after LT.

    Dr. Siddiqui is a member of the Liver Forum and was the lead author on the NAFLD Case Definition manuscript. He is part of the AASLD Liver Transplantation Education Committee. Additionally, he is an active member of the AASLD NAFLD and Liver Transplantation SIG. He remains active within the NAFLD research space serving as the site-PI for multiple clinical trials and was the national PI for the multi-center NASH trial for the saroglitazar. He is also an active member of the NailNASH consortium, which is a multi-center collaboration between academic centers across the US that aims to better understand post-liver transplant NAFLD. In addition to his clinical and research involvement, he is an active teacher and educator at Virginia Commonwealth University. He mentors many trainees from undergraduates, post-graduate and medical students, residents and fellows.

    Alina M. Allen

    Alina M. Allen, MD is an assistant professor of medicine in the Division of Gastroenterology and Hepatology and the director of the NAFLD Clinic at Mayo Clinic Rochester, Minnesota. She is an NIH-funded investigator in the field of nonalcoholic fatty liver disease (NAFLD) with clinical expertise in liver diseases before and after liver transplantation. Her research interest includes the development of noninvasive biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and pathways to improve the identification and management of patients with NAFLD. Her research program includes biorepositories/biomarker databases, longitudinal population-based studies of natural history and clinical trials.

    Dr. Allen is actively involved in national societies as a member of the NAFLD Special Interest Group within the American Association for the Study for Liver Diseases (AASLD) and as a GRADE methodologist of the Clinical Practice Guideline Committee of the American Gastroenterology Association. She serves on the Editorial Board of HEPATOLOGY, the AASLD Publications Committee and the Annual Meeting Education Committee. She has served as chair of the AGA Abstract Committee for Non-Alcoholic Fatty Liver Diseases (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) for the past three years.

    Kathleen E. Corey (Moderator)

    Kathleen Corey, MD, MPH, MMSc is the director of the Massachusetts General Hospital Non-Alcoholic Fatty Liver Disease (NAFLD) Clinic, associate program director for the medicine residency for clinical and translational research, hepatologist with a specialty in NAFLD, physician investigator in the CTEU and an assistant professor of medicine at Harvard Medical School. Dr. Corey earned her medical degree at Duke University School of Medicine, her master’s in public health from the University of North Carolina and master’s in medical science from Harvard Medical School. Prior to joining the faculty of Massachusetts General Hospital (MGH), she completed her training in internal medicine, chief residency, gastroenterology and advanced hepatology and liver transplant at MGH.

    Dr. Corey’s interests include clinical and translational research in NAFLD. She aims to better understand predictors of development and progression of NAFLD, the interplay between cardiovascular disease and NAFLD and the natural history of NAFLD in persons living with HIV (PLWH). She is the co-private investigator for an R01 evaluating the role of tesamorelin, a growth hormone-releasing hormone for the treatment of NAFLD and is involved in an NIH-funded study on the prevalence, risk factors and treatment of NAFLD in PLWH.

  • 2021 Webinar: Developing a Career in Clinical Research

    Contains 2 Component(s) Recorded On: 02/10/2021

    Webinar hosted by the Hepatitis B Special Interest Group on February 10, 2021.

    This live webinar will focus on identifying areas of unmet needs and developing a research career. We will have four presenters share their career experiences. An experienced professional will share her experience on doing clinical research in hepatitis B and thoughts on selecting between research, quality improvement or medical educator. Three young investigators will present their perspectives on how his or her career started and share in future career plans.

    Anna S. Lok

    Anna S. Lok, MD, FAASLD graduated from the University of Hong Kong Medical School. She completed her hepatology training in London under Dame Sheila Sherlock at the Royal Free Hospital in London. She was faculty at the University of Hong Kong before moving to the United States. She joined the University of Michigan in 1995 as director of the hepatology program and in 2016 became assistant dean for clinical research. Dr. Lok’s research focuses on natural history and treatment of hepatitis B and C. She has published more than 550 papers on viral hepatitis and liver diseases, including five editions of the American Association for the Study of Liver Diseases (AASLD) guidelines on "Hepatitis B."

    Dr. Lok has mentored more than 50 residents, fellows, and faculty, many of whom are now full professors and heads of hepatology units. Dr. Lok received many awards throughout her career including awards from the Hepatitis B Foundation, the American Gastroenterological Association, the Canadian Association for the Study of the Liver, the European Association for the Study of the Liver, and the Distinguished Service Award from the AASLD in 2011. Dr. Lok served as associate editor of HEPATOLOGY (2002-2006), co-editor of Journal of Viral Hepatitis (2007-2009), senior associate editor of GASTROENTEROLOGY (2011-2012), and president of AASLD (2017).

    Kali Zhou

    Kali Zhou, MD, MAS is a transplant hepatologist and assistant professor in the Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California. She received her medical degree from Feinberg School of Medicine at Northwestern University, completed an internal medicine residency at the University of California, Los Angeles, and a T32 gastroenterology and transplant hepatology fellowship at the University of California, San Francisco, where she also completed a master’s in clinical research. She holds committee positions in the AASLD HBV and Public Health SIGs.

    Dr. Zhou investigated the epidemiology of HCV in Southern China as a Fulbright scholar and has published numerous peer-reviewed manuscripts and reviews related to epidemiology and health services delivery for chronic HBV infection. Her current research program focuses on disparities in liver cancer and utilizing novel geospatial approaches to improve cancer equity and outcomes for multi-ethnic populations. She is also grant funded to study the impact of immigration and acculturation on completing guideline-based HBV metrics. She was awarded the Early Career Investigator Award in Clinical/Translational Science by AASLD for her work.

    Hannah Lee

    Hannah Lee, MD is an assistant professor of medicine at Virginia Commonwealth University Medical Center in Richmond, Virginia in the division of GI, Hepatology and Nutrition. She has a strong interest in liver cancer and viral hepatitis, particularly hepatitis B. She was previously the director of the Asian Pacific Liver Health Program in Boston Chinatown at Tufts Medical Center. She is currently co-director of the multidisciplinary liver cancer program at VCU and practices both transplant and general hepatology. She is involved in multicenter studies evaluating the natural history of HBV and HCC.

    Dr. Lee’s career has been focused on addressing health disparities in liver disease, particularly among disproportionately affected minority groups with chronic hepatitis B. Some of her work has focused on screening and linkage to care. She has been involved in education and outreach both locally and nationally in addressing liver health disparities in hepatitis B and hepatocellular carcinoma among various communities in the United States. Dr. Lee currently serves on the AASLD Hepatitis B Special Interest Group's Leadership Steering Committee and is co-chair of the Education Subcommittee. She also serves as a committee member on the AASLD Public Policy Committee.

    Yao-Chun Hsu

    Yao-Chun Hsu, MD, MSc, PhD is currently an associate professor at the school of medicine, I-Shou University, and the director of the Center for Liver Diseases, E-Da Hospital, both of which were in Kaohsiung, Taiwan. He is an active physician with a large clinical practice in inpatient and outpatient care, as well as sonography and endoscopy service. He is also an active researcher in clinical and translational research for chronic liver diseases, with a focus on chronic viral hepatitis, particularly viral hepatitis B. He has more than 100 peer-reviewed publications to his credit, including first authorship of original research articles published in leading journals such as Lance Infectious Diseases, Lancet Gastroenterology and Hepatology, Gut, Journal of Hepatology and HEPATOLOGY.

    Dr. Hsu has served as an associate editor in the liver section for Digestive Diseases since 2018 and has joined the editorial board for Journal of Gastroenterology and Hepatology since 2017. He leads the research team for chronic viral hepatitis in E-Da Hospital and takes part in more than 10 multicenter trials as the principal investigator at his site. Moreover, he is eagerly participating in international collaboration and has been actively working with researchers from the United States, Canada, Japan, China, Hong Kong, and so on. His academic contributions have been recognized with awards such as the 28th Professor Sung Juei-Low's Academic Award for Excellent Research, Annual Research Award for Liver Disease Prevention and Treatment (awarded by the Taiwan Liver Disease Prevention & Treatment Research Foundation), and Young Investigator Award at the Asian Pacific Association for the Study of the Liver Single Topic Conference.

    Mindie H. Nguyen (Moderator)

    Mindie H. Nguyen, MD, MAS, FAASLD is a professor of medicine and director for the Hepatology Fellowship and Clerkship in the Division of Gastroenterology and Hepatology and Liver Transplant at Stanford University Medical Center. She is an active clinician with a large general and transplant liver practice, and an active researcher in viral hepatitis, non-alcoholic fatty liver disease and liver cancer with over 250 publications including first or senior authorship in leading journals such as The New England Journal of Medicine, Lancet Gastroenterology and Hepatology, Gastroenterology, Journal of Hepatology and HEPATOLOGY.

    Dr. Nguyen has served as editorial/advisory board member for major journals such as Lancet Gastroenterology and Hepatology, Gastroenterology and HEPATOLOGY. She is currently Chair of the Hepatitis B Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and an Officer/Treasurer and Executive Governing Council for the International Association for the Study of Liver Diseases (IASL). She is the lead Principal Investigator for several multinational studies involving over 40 centers in the U.S. and Asia Pacific. She serves as Board of Directors or Advisors for non-profit organizations locally and nationally in the U.S; and in collaboration with the local country Ministries of Health and Sports, she has directed scientific programs of continuing medical conferences for physicians in Mongolia and Myanmar. As an active teacher and educator, she has mentored over 130 trainees from high school students to undergraduate, medical, Masters’ and PhD students in Public Health/Epidemiology, clinical residents/fellows, postdoctoral research fellows, and faculty at Assistant/Associate Professor rank from Stanford University as well as other institutions in the U.S. and overseas.

    Yee Hui Yeo (Moderator)

    Yee Hui Yeo, MD, MSc is a resident doctor at Cedars-Sinai Medical Center. He is an active investigator on viral hepatitis related epidemiological and health outcomes research. He is currently a trainee member of the Hepatitis B SIG Steering Committee, AASLD. He has published more than 40 peer-reviewed publications, including first or co-first authorship of original articles published in Gastroenterology, Journal of Hepatology, HEPATOLOGY and Gut.

    Dr. Yeo has served as associate editor for BMC Gastroenterology. He is interested in harnessing health data analytic tools, modeling, and meta-analysis to determine the epidemiology, cascade of care, natural history, and outcomes of chronic viral hepatitis infection. He uses large databases, multicenter cohorts and EHR data from Cedars-Sinai Medical Center. He has been participating in international consortia of natural history of hepatitis B infection. His works were selected as "Best of the Liver Meeting" in AASLD annual meeting 2018. Yeo is the recipient of "Emerging Liver Scholar Award" in 2019.

  • 2021 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy

    Contains 2 Component(s) Recorded On: 01/20/2021

    Webinar hosted by the Hepatitis B Special Interest Group on January 20, 2021.

    This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended. We will conclude with a twenty-minute discussion on the gaps in current knowledge, whether and how the practice can be individualized.

    Wen-Juei Jeng

    Rachel Wen-Juei Jeng, MD received her Doctor of Medicine Education from College of Medicine, National Yang-Ming University, Taiwan (1998-2005). She has accomplished internal medicine residency, Gastroenterology fellowship training and becomes a faculty and physician scientist in Department of Gastroenterology and Hepatology in Chang Gung Memorial Hospital, Linkou branch, Taiwan. She currently serves as an Associate Professor in College of Medicine, Chang Gung University since 2019.

    Dr. Jeng’s research interests mainly focus on viral hepatitis (esp. HBV) and clinical hepatology. She has been working with her mentor Prof. Yun-Fan Liaw and published a series of off-Nuc therapy cohort study in Hepatology and Clinical Gastroenterology and HEPATOLOGY. She now serves as a member of TASL, EASL and AASLD.

    Harry Janssen

    Harry Janssen, MD, PhD, FAASLD is a professor of medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in hepatology. He currently works at Toronto General Hospital as chief of hepatology and director of the Toronto Centre for Liver Disease.

    Dr. Janssen graduated from medical school in the Netherlands. During his study he spent one year as research student in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in hepatitis B. Following his training in Internal Medicine and Gastroenterology in the Netherlands, he returned to the Mayo Clinic for a Research Fellowship in Hepatology. In 2001, he became a faculty member and in 2006 he was appointed as full professor of medicine and chief of the Section Liver Diseases and Transplantation in Rotterdam. In 2013, he came to Canada where he merged three liver programs into the Toronto Centre for Liver Disease, based at the Toronto General Hospital, University Health Network.

    Dr. Janssen has coordinated numerous clinical and translational studies on treatment for chronic viral hepatitis and other liver diseases. His main research interest is cure of chronic hepatitis B. He has published more than 500 original peer-reviewed papers and many book chapters. His H-index is over 100 and he has been cited 45,000 times (Google Scholar). He has received several prestigious international awards and has mentored over 50 PhD students, of whom many have taken leadership positions in the field of hepatology or virology.

    Marc Ghany (Moderator)

    Marc G. Ghany, MD, MHSc, FAASLD is an investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis.

    Yao-Chun Hsu (Moderator)

    Yao-Chun Hsu, MD, MSc, PhD is currently an associate professor at the school of medicine, I-Shou University, and the director of the Center for Liver Diseases, E-Da Hospital, both of which were in Kaohsiung, Taiwan. He is an active physician with a large clinical practice in inpatient and outpatient care, as well as sonography and endoscopy service. He is also an active researcher in clinical and translational research for chronic liver diseases, with a focus on chronic viral hepatitis, particularly viral hepatitis B. He has more than 100 peer-reviewed publications to his credit, including first authorship of original research articles published in leading journals such as Lance Infectious Diseases, Lancet Gastroenterology and Hepatology, Gut, Journal of Hepatology and HEPATOLOGY.

    Dr. Hsu has served as an associate editor in the liver section for Digestive Diseases since 2018 and has joined the editorial board for Journal of Gastroenterology and Hepatology since 2017. He leads the research team for chronic viral hepatitis in E-Da Hospital and takes part in more than 10 multicenter trials as the principal investigator at his site. Moreover, he is eagerly participating in international collaboration and has been actively working with researchers from the United States, Canada, Japan, China, Hong Kong, and so on. His academic contributions have been recognized with awards such as the 28th Professor Sung Juei-Low's Academic Award for Excellent Research, Annual Research Award for Liver Disease Prevention and Treatment (awarded by the Taiwan Liver Disease Prevention & Treatment Research Foundation), and Young Investigator Award at the Asian Pacific Association for the Study of the Liver Single Topic Conference.

  • 2021 Webinar: Practical Approach to Coagulation Management in Cirrhosis

    Contains 2 Component(s) Recorded On: 01/11/2021

    Webinar hosted by the Clinical Practice Special Interest Group on January 11, 2021.

    Coagulation disorders in patients with cirrhosis present challenging situations for clinical providers. This one hour webinar will summarize the knowledge behind coagulation disorders in patients with cirrhosis, including the mixed and thrombosis prone model, limitations in current tests of hemostasis, and the dangers of excessive transfusion. Using practical clinical vignettes, learners will gain understanding of best practice to manage these difficult coagulation situations, including in practice settings where colleagues in hospital medicine and interventional radiology may have different approaches. Vignettes will include an outpatient cirrhotic patient with portal vein thrombosis, an inpatient cirrhotic requiring paracentesis, and an inpatient cirrhotic in the intensive care unit with renal failure and spontaneous mucosal bleeding.

    Nicolas Intagliata

    Nicolas Intagliata, MD is an associate professor of medicine at the University of Virginia. His research is based in hemostasis and liver disease. More specifically, the role of anticoagulation in prevention and treatment of thrombosis in cirrhosis and underlying mechanisms of hemostasis and thrombosis in liver disease. His clinical practice involves caring for patients both in the general hepatology and liver transplantation setting.

    Arul Thomas (Moderator)

    Arul M. Thomas, MD is an assistant professor of medicine at the MedStar Georgetown Transplant Institute at Georgetown University Hospital, in Washington, DC. He has interests in all aspects of clinical transplant hepatology, including autoimmune liver diseases, drug induced liver injury and pediatric to adult transition of care. He serves on the Clinical Practice SIG. He practices also at MedStar Washington Hospital Center, where he fulfills a goal to increase access to advanced liver care in underserved communities in the DC area. At all his clinical sites, he is well-known as an avid educator of trainees.

  • 2020 Webinar: New E/M Requirements are Coming January 1: Will You Be Ready?

    Contains 2 Component(s) Recorded On: 12/15/2020

    Webinar hosted by the Public Policy Committee on December 15, 2020.

    On January 1, 2021, the Centers for Medicare & Medicaid Services will be implementing significant changes to the outpatient evaluation and management (E/M) codes (CPT® codes 99202-99215) for new and established patients. The agency revised both the documentation requirements and values. Practices, physicians, and staff must understand these modifications to ensure a successful transition next year. To help prepare, AASLD is holding a webinar to explain these changes, including how to correctly bill and document the revised code set, on December 15 at 3pm ET. Join to learn more about what these changes mean for you and your practice to be prepared on January 1!

    Erika Miller

    Erika Miller, JD, Senior Vice President and Counsel, has 17 years of experience in government relations and has broad experience in Medicare reimbursement policies and appropriations working largely with non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations. Erika has expertise in the intricacies of Medicare coding and reimbursement and provides guidance to clients as they navigate the evolving area of health care payment and quality. Erika is a co-author of a chapter entitled, “Lobbying the Appropriations Process” in the American Bar Association Lobbying Manual.

    A New Jersey native, Erika worked in the office of Congressman Steve Rothman of New Jersey where she handled immigration issues. Erika also worked in the U.S. Department of Health and Human Services Office on Women's Health, where she monitored grant awards. Prior to joining CRD Associates in 2005, Erika worked at the lobbying firm of Broydrick & Associates representing health care interests. She served as co-chair of the Women in Government Relations Health & Social Polices Task Force and is member of the group Women Business Leaders in Health Care. Erika received her law degree from The American University, where she was an editor of the Administrative Law Review. She earned an undergraduate degree in Political Science from Colgate University. 

  • 2020 Webinar: Chronic Hepatitis C 500: The Advanced Course

    Contains 2 Component(s) Recorded On: 12/02/2020

    Webinar hosted by the Hepatitis C Special Interest Group on December 2, 2020.

    Many HCV-infected patients suffer from decompensated cirrhosis. Aside from appropriate care of their cirrhosis, these patients may benefit from therapy, irrespective of liver transplant candidacy. Providers outside of transplant centers, should be knowledgeable about pertinent aspects of liver transplants for their patients. Finally, several groups have reported unusual genotype subtypes which are less responsive to existing DAA regimens. This webinar is designed for the experienced HCV-treatment provider.

    Brian Pearlman

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

    Preeti A. Reshamwala

    Preeti A. Reshamwala, MD is a Distinguished Physician in Transplant Hepatology at Emory University School of Medicine. She is the director of The Fatty Liver Clinic, and the program director for the Transplant Hepatology Fellowship Program.

    Dr. Reshamwala has participated in over 21 clinical trials on the treatment of Hepatitis C. She co-directs the management and treatment of patients with hepatitis C who are on the waitlist for liver transplantation at Emory University, and hepatitis C treatment for patients after transplantation. She has been an advocate for using hepatitis C positive donors for liver transplant recipients who have not been exposed to Hepatitis C.

    Jean-Michel Pawlotsky

    Jean-Michel Pawlotsky, MD, PhD is professor of medicine at the University of Paris-Est. He is the director of the National Reference Center for Viral Hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and director of research team “Viruses-Hepatology-Cancers“ at the Mondor Institute of Biomedical Research (INSERM U955). He focuses on teaching and research in virology (primarily hepatitis viruses) and liver oncology. Dr. Pawlotsky earned his medical degree in Hepatology and Gastroenterology in 1992. In addition, he earned a Thesis in molecular virology from the University of Paris, France, and he is a graduate in virology from the Pasteur Institute in Paris and microbiology from the University of Paris. Dr. Pawlotsky has been acting as the Secretary General of the European Association for the Study of the Liver (EASL) between 2005 and 2009.

    Dr. Pawlotsky is a member of the Strategic Committee of the National Agency for Research on AIDS and Viral Hepatitis (ANRS). He has been an associate editor of HEPATOLOGY, the official journal of the American Association for the Study of Liver Diseases (AASLD), between 2001 and 2006, and an associate editor of Gastroenterology, the official journal of the American Gastroenterological Association (AGA), between 2011 and 2016. Dr. Pawlotsky’s noted career contributions include the publication of over 500 articles and book chapters in his areas of expertise and over 650 invited lectures at international meetings.

    Omar Massoud (Moderator)

    Omar Massoud, MD, PhD, FAASLD is an associate professor of medicine at the University of Alabama at Birmingham. He is the director of clinical liver research at the University of Alabama Liver Center. He is a member of the AASLD Publication Committee and Hepatitis C Special Interest Group Steering Committee. He earned his Doctor of Medicine degree from Al-Azhar University, Cairo, Egypt. He completed residency in Internal Medicine at Case Western Reserve University, Cleveland, Ohio, followed by Fellowship in Gastroenterology and Hepatology at the Medical College of Wisconsin, Milwaukee, Wisconsin. He completed a fellowship in Transplant Hepatology at Mayo Clinic, Rochester, Minnesota.

    Dr. Massoud was the PI of the large CDC study on Birth Cohort HCV screening (2011-2016). The results of this study lead to change in HCV screening national guidelines. He is also the PI of several government and industry sponsored studies on HCV and NASH. He has numerous publications and presentations on HCV and NASH. He mentored many trainees and young faculty throughout their career.

    Photo of Omar Massoud, MD, PhD, FAASLD

  • Fundamentals of Liver Disease - Hepatitis B 2.0

    Contains 25 Component(s), Includes Credits Recorded On: 10/15/2020

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    HBV: Epidemiology and Screening
    Patient with Positive Hepatitis B Serologies
    Natural History of HBV and Identification of Treatment Candidates
    Management of the Chronic HBV Patient with Co-morbid and Other Conditions
    Antiviral Treatment of the Patient with Chronic HBV
    Prevention of HBV Infection
    Hepatitis B in the Pediatric Patient

    Release date: October 15, 2020
    Expiration date: October 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 3.50 AMA PRA Category 1 Credits™   
    Continuing Education (CE): For a maximum of 3.50 Contact Hour 
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 3.50 MOC Points


    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:

    -7 online interactive, narrated modules 20 to 30 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 3.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 3.50 MOC Points
    Continuing Education (CE): For a maximum of 3.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 3.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 3.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 3.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by October 14, 2023

    CLAIMING CE CREDITS
    Nurses for a maximum of 3.50 contact hours for this enduring continuing education material must be completed by October 14, 2023

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by October 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through October 2023 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    Marc G. Ghany

    Marc G. Ghany, MD, MHSc, FAASLD is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Tram T. Tran

    Tram T. Tran, MD, FAASLD is the Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Norah A. Terrault

    Norah A. Terrault, MD, MPH, FAASLD is a Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a master’s in public health at the University of California at Berkeley. 

    Dr. Terrault has focused her clinical and research activities on viral hepatitis and non-alcoholic fatty liver disease, especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and fatty liver, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIH-supported HBV clinical research network (HBRN) and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored 330 peer-reviewed manuscripts, editorials, invited reviews as well as US national guidelines for treatment of chronic hepatitis B and C. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. 

    Dr. Terrault is the founder of ECHO-Plus, a multifaceted program to train and support primary care physicians in California to care for patients with hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators. Dr. Terrault was recently elected as Councilor to the AASLD governing board and will serve as president in 2023.

    Marion G. Peters

    Marion G. Peters, MBBS, MD, FAASLD is an Emeritus Professor of Medicine at the University of California at San Francisco and Adjunct Professor of Medicine at Northwestern University, Chicago. She is a hepatologist with a particular interest in viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection.  She led the NIH AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group (TSG) for 4 years where she championed young investigators to be chairs of new trials in Hep TSG. She is the Protocol Facilitator for ACTG Hepatitis TSG HBV-related studies, focusing on the development of US and international studies for new drugs for patients with HBV, with and without HIV. She is currently a team member or co-chair of 4 ACTG hepatitis trials. She is also a member of the HEP TSG steering committee.

    Dr. Peters serves on the scientific Advisory Board of International Antiviral Society USA, HEP DART and is a senior advisor to International Coalition to Eliminate HBV. She is an editor for the Journal of Antimicrobial Chemotherapy. She has trained fellows, house staff and medical students in clinical and translational research, many of whom have gone on to faculty positions focusing on liver disease. She has mentored faculty and fellows in her institution, nationally and internationally. She is particularly focused on mentoring women in medicine.  She has numerous publications on viral hepatitis with and without HIV coinfection in peer-reviewed journals with multiple collaborators.




    Anna S. Lok

    Anna S. Lok, MD, FAASLD graduated from the University of Hong Kong Medical School. She completed her hepatology training in London under Dame Sheila Sherlock at the Royal Free Hospital in London. She was faculty at the University of Hong Kong before moving to the United States. She joined the University of Michigan in 1995 as director of the hepatology program and in 2016 became assistant dean for clinical research. Dr. Lok’s research focuses on natural history and treatment of hepatitis B and C. She has published more than 550 papers on viral hepatitis and liver diseases, including five editions of the American Association for the Study of Liver Diseases (AASLD) guidelines on "Hepatitis B."

    Dr. Lok has mentored more than 50 residents, fellows, and faculty, many of whom are now full professors and heads of hepatology units. Dr. Lok received many awards throughout her career including awards from the Hepatitis B Foundation, the American Gastroenterological Association, the Canadian Association for the Study of the Liver, the European Association for the Study of the Liver, and the Distinguished Service Award from the AASLD in 2011. Dr. Lok served as associate editor of HEPATOLOGY (2002-2006), co-editor of Journal of Viral Hepatitis (2007-2009), senior associate editor of GASTROENTEROLOGY (2011-2012), and president of AASLD (2017).

    Brian McMahon

    Brian J. McMahon MD, FAASLD is Director of the Liver Disease and Hepatitis Program at the Alaska Native Medical Center (ANMC) in Anchorage, Alaska. Dr. McMahon has served as co-author of the AASLD Practice Guideline for Hepatitis B between 2009 and 2018 and is co-Author of the AASLD Hepatitis B Guidance 2019. He was also the co-chair of the WHO Hepatitis Guideline published in 2015. He directed a program that halted transmission of hepatitis B in the Alaska Native population in the 1980’s, the only US born population endemic for persons with chronic hepatitis B. He oversees the management and care of over 1,000 Alaska Native persons with chronic hepatitis B.

    Dr. McMahon has served on the editorial board of Hepatology. He was previously chair of the AASLD Practice Guidelines Committee, was on the AASLD Nominating Committee and was previously chair of the Hepatitis B SIG. He received the AASLD distinguished Mentor/Clinician Award for 2017 for contributions in the global elimination of hepatitis B. He has received multiple NIH and CDC research grants and directs a team of investigators in Alaska. He conducts research in Alaska Native People including hepatitis A and B vaccine long-term efficacy, hepatitis B and C outcome, autoimmune liver diseases and NAFLD. He also has been involved in two hepatitis B projects funded by the Global AIDS program and the CDC Foundation in Tanzania and Zanzibar Africa. He teaches medical students at the University of Alaska/University of Washington WWAMI program, precepts medical students, residents in hepatology clinic and mentors medical students’ research projects. He holds a position as a Research Associate at the Arctic Investigations Program of the CDC located on the ANMC campus in Anchorage. He is Clinical Professor of Medicine at the University of Washington, School of Medicine in Seattle and Auxiliary Professor of Health Sciences at the University of Alaska, Anchorage. He has published over 160 peer review original articles plus over 50 review articles, guidelines/guidance statements and editorials.

    Maureen M. Jonas

    Maureen M. Jonas, MD, FAASLD is the Director of the Center for Childhood Liver Disease in the Division of Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital, and Professor of Pediatrics at Harvard Medical School.  Her area of expertise is Pediatric Hepatology and Liver Transplantation, with a special emphasis on viral hepatitis in children. She is the author of a number studies of therapies for pediatric viral hepatitis.

    Dr. Jonas has served on several AASLD committees, including the Practice Guidelines Committee, Ethics Committee and Nominating Committee.  She chaired several symposia sponsored by AASLD and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition at AASLD annual meetings.  She has served as abstract reviewer for AASLD meetings, and ad hoc reviewer for Hepatology.  Jonas established the Pediatric Transplant Hepatology training Program at Boston Children’s Hospital and served as its director until 2016.  She was the Medical Director of the Liver Transplant Service at BCH from 1991 through 2014. As an active educator, she has mentored numerous pediatric gastroenterology and hepatology fellows, as well as junior faculty, over the last 30 years.  She currently serves on the Transplant Hepatology Examination Committee for the American Board of Pediatrics.  She has been the lead Principal Investigator for many multinational pediatric viral hepatitis trials and has lectured extensively on this topic around the country and around the world.

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Marc G. Ghany, MD, MHSc, FAASLD
    Faculty
    Nothing to disclose

    Tram T. Tran, MD, FAASLD
    Faculty
    Employment: Gilead Sciences (Unrelated)

    Norah Terrault, MD, MPH, FAASLD
    Faculty
    Grant/Research Support: Gilead Sciences and Roche/Genetech

    Marion G. Peters, MD, FAASLD
    Faculty
    Faculty/Advisory Committee or Review Panels: Antios, Atea and Aligos
    Employment (Spouse): Genentech Research and Development (subsidiary of Roche)

    Anna S.F. Lok, MD, FAASLD
    Faculty
    Advisory Board: CLEAR-B, Gilead Sciences, GlaxoSmithKline, Huahui, Roche, Spring Bank, and TARGET PharmaSolutions
    Grant/Research Support: Assembly Biosciences, Bristol Myers Squibb, Gilead Sciences, and TARGET PharmaSolutions (to University of Michigan)

    Brian J. McMahon, MD, FAASLD
    Faculty
    Grant/Research Support: Gilead Sciences - Grant received by department at institution and not directly.

    Maureen M. Jonas, MD, FAASLD
    Faculty/Advisory Committee or Review Panels: Served as chair of DSMB for Gilead Sciences
    Grant/Research Support: AbbVie, Gilead Sciences, Roche and Merck. Echosens (equipment only)

    Lauren A. Beste, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Nothing to disclose 

    Amanda J. Chaney, DNP, APRN, FNP-BC 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Royalities: Springer Publishing-Author 

    Leslie Hayes, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Nothing to disclose 

    Vicki Shah, PA 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board 

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Denise Seise 
    AASLD Staff 
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff 
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.


  • 2020 Webinar: Treatment Strategies for Autoimmune Hepatitis Beyond First-line Therapy

    Contains 2 Component(s) Recorded On: 10/14/2020

    Webinar hosted by the Cholestatic and Autoimmune Liver Diseases Special Interest Group on October 14, 2020.

    Treatment failure. Incomplete response. Treatment intolerance. Management of autoimmune hepatitis can be extremely challenging when first-line therapy is inadequate. Join us for a discussion of alternative treatment options for autoimmune hepatitis and a review of their efficacy. Learn about updates to the treatment paradigm from the new 2019 guidelines!

  • 2020 Webinar: Novel Models for HCV Care Delivery

    Contains 2 Component(s) Recorded On: 10/06/2020

    Webinar hosted by the Hepatitis C Special Interest Group on October 6, 2020.

    In order to achieve the World Health Organization's goal of treating at least 80% of identified HCV-infected patients, novel models of HCV care delivery should be implemented. This webinar will address telemedicine and digital telemedicine with respect to HCV care and will attempt to demonstrate improved models of linkage to care in both urban and exurban settings.

    John D. Scott

    John Scott, MD, MSc is a Professor of Medicine (Division of Allergy and Infectious Diseases) and Medical Director of Digital Health at the University of Washington. He graduated from Stanford University with a degree in Human Biology, attended Georgetown University School of Medicine cum laude, completed a residency in Internal Medicine at Stanford University Hospitals, and then obtained sub-specialty training in Infectious Diseases at the University of Washington.

    In 2009, he launched Project ECHO (Extension for Community Health Outcomes) in Washington State, the first place to replicate the ECHO model outside of New Mexico. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of common, complex, chronic diseases. In 2015, he won the Warren Reid Award for excellence in health care for the state of Washington, in recognition of his telehealth work. He chairs the Washington State Telehealth Collaborative and serves on the Telehealth committee for the Infectious Disease Society of America.

    Jennifer C. Price

    Jennifer Price, MD, PhD is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and Director of the UCSF Viral Hepatitis Center. Her research examines the contributions of novel and traditional factors associated with liver disease and fibrosis progression in large observational HIV cohorts, with or without viral hepatitis. Dr. Price is a PI of the San Francisco Bay Area site of the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS), which integrates two of the largest and longest running NIH-funded prospective cohorts of men and women with and at risk for HIV in the U.S. She also serves as co-Chair of the MWCCS Liver Working Group and Vice Chair of the AASLD HCV SIG. Dr. Price is a member of the End Hep C SF Coordinating Committee and leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She is the founding director of the DeLIVER Care Van, a mobile unit aimed at improving access to HCV screening and high-quality liver-related health care among marginalized communities.

    Sally Hodder

    Sally Hodder, MD is a Professor Medicine, Associate Vice President for Clinical and Translational Research at West Virginia University and Director and Principal Investigator (PI) of the West Virginia Clinical and Translational Science Institute. A graduate of Case Western Reserve University School of Medicine, she has been on the front lines of the HIV epidemic since she was an intern at the University of California San Francisco in 1980. After completing infectious diseases fellowship training, she saw first-hand the emergence of AIDS in Africa while working on a Schistosomiasis haematobium project in Coast Province, Kenya. Subsequently, she has had extensive experience leading large scientific programs (both academia and pharma). From 2003-2005, she served as Vice President of Virology Medical Affairs, Bristol-Myers-Squibb. In 2005, Dr. Hodder was recruited to New Jersey Medical School in Newark, New Jersey to build an HIV program where HIV prevalence was nearly 3% among the African American community. She served as Medical Director for a large HIV clinic in Newark and was successful in obtaining funding for both HIV treatment and prevention trials. She served as Protocol Chair for the NIH-funded HIV Prevention Trials Network 064 trial, a study of HIV incidence and risk behaviors among 2,099 U.S. women. In 2014, West Virginia University recruited Dr. Hodder to direct and serve as Principal Investigator of the West Virginia Clinical and Translational Science Institute, funded by the NIH. During her tenure, the West Virginia Practice-Based Research Network was developed which now includes 107 primary care sites across West Virginia, the Extension for Community Healthcare Outcomes (ECHO) to enhance rural primary care providers’ knowledge was implemented, and opioid use disorder and resultant emergent epidemics (e.g., hepatitis B, C, and HIV) were made a programmatic focus. She again finds herself on the front lines as HIV outbreaks are emerging in West Virginia.

    Lisa Catalli (Moderator)

    Lisa Catalli is a Nurse Practitioner at the University of California, San Francisco’s Viral Hepatitis Center and Liver Transplant Clinic. She earned her Master’s Degree from UCSF School of Nursing in 1995 and has been working in the field of Hepatology since 2010. She has been treating HCV since the dawn of direct-acting antiviral therapy, and served as a co-investigator in several multi-center clinical trials. Her expertise in HCV treatment has led to multiple educational and leadership activities in HCV elimination. She has worked to disseminate knowledge about HCV through mentoring students and didactic presentations and workshops. She is a key clinical faculty in the UCSF Project ECHO program which uses multi-point video conferencing to build knowledge-sharing networks with community providers to build the capacity for care of HCV patients throughout California.

    She is also part of an interdisciplinary team to improve access and linkage to HCV care through a creative, innovative model of mobile liver care clinic (UCSF DeLiver Care) that is co-localized at syringe exchange/medically assisted treatment centers for vulnerable populations. She has been a Hepatology Associates member of AASLD for 10 years with leadership roles in the HCV SIG and the Hepatology Associates Committee, serving on committees for the planning of AASLD educational programs, moderating educational sessions, and selecting NP/PA fellowship awards.